← SynDRA
PIBRENTASVIR
SynDRA canonical compound SYN0038226 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | NS5A |
|---|
| Mechanism of action | antiviral |
|---|
| Indication | hepatitis c |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
Drug classes
- Cytochrome P450 1A2 Inhibitors
- P-Glycoprotein Inhibitors
- Organic Anion Transporting Polypeptide 1B1 Inhibitors
- Organic Anion Transporting Polypeptide 1B3 Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Cytochrome P450 3A Inhibitors
- Hepatitis C Virus NS5A Inhibitor
- UGT1A1 Inhibitors
ATC classes
Cross-references
Synonyms
- ABT-530
- A-1325912.0
- Pibrentasvir component of mavyret
- Glecaprevir; pibrentasvir
- Maviret
- Mavyret
- Glecaprevir / pibrentasvir
- Glecaprevir and pibrentasvir
- ABT-493/ABT-530
- Glecaprevir mixture with pibrentasvir
- ABT-493 / ABT-530
- S900007520
- ABT 530
- 2WU922TK3L
- pibrentasvirum
- RefChem:863096
- DTXCID501513514
- Pibrentasvir [USAN]
- Abt530
- Pibrentasvir (ABT-530)
- C57H65F5N10O8
- UNII-2WU922TK3L
- ABT-530;Pibrentasvir
- PIBRENTASVIR [MI]
- Pibrentasvir(ABT-530)
- PIBRENTASVIR [INN]
- PIBRENTASVIR [JAN]
- Pibrentasvir(ABT-530)?
- PIBRENTASVIR [WHO-DD]
- orb1302066
- Pibrentasvir (JAN/USAN/INN)
- SCHEMBL2756579
- SCHEMBL17639956
- SCHEMBL29378105
- SCHEMBL30184998
- GTPL11268
- EX-A865
- PIBRENTASVIR [ORANGE BOOK]
Reported adverse events
- Angioedema
- Fatigue
- Headache
- Nausea
Look up PIBRENTASVIR in the interactive SynDRA portal →